Beam Therapeutics Inc. (BEAM)
NASDAQ (NGS) NASDAQ (NGS) Primary 
XMEX 
3 Gene Editing Stocks with Potential to Transform Medicine
Gene editing holds substantial promise for treating thousands of diseases – creating incredible opportunities for gene editing stocks. It could help treat the 7,000 diseases caused by genetic disorders, most of which occur with gene mutation.
Beam Therapeutics (BEAM) Q2 Earnings Beat, Revenues Miss
Beam Therapeutics (BEAM) reports mixed second-quarter results. The company remains focused on pipeline development.
Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Misses Revenue Estimates
Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1.11 per share versus the Zacks Consensus Estimate of a loss of $1.13. This compares to loss of $1.08 per share a year ago.
Beam Therapeutics (BEAM) Soars 7.9%: Is Further Upside Left in the Stock?
Beam Therapeutics (BEAM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Trade of the Day: Buy Beam Therapeutics Call Options as BEAM Stock Heads to $40
Speculators seeking a big pop over the next few months should consider a high-risk, high-reward position in Beam Therapeutics (NASDAQ: BEAM ). According to its public profile, Beam specializes in precision genetic medicines, which is a growing and viable market.
3 Gene Editing Stocks Shaping the Future of Medicine
Gene editing stocks represent one of the biggest investing trends in biopharma in recent years. The gene editing field employs advanced technologies to edit the DNA of different organisms, thereby opening up possibilities for transformative treatment options.
Beam Therapeutics' (BEAM) CFO to Step Down, Stock Declines
Beam Therapeutics' (BEAM) current chief financial officer, Terry-Ann Burrell, is set to step down from her role on Aug 9. The stock falls 4.7%.
Here's Why You Should Invest in Beam Therapeutics (BEAM) Now
Here, we discuss why investing in Beam Therapeutics (BEAM) stock now may be a prudent move.
Beam Therapeutics (BEAM) Upgraded to Buy: What Does It Mean for the Stock?
Beam Therapeutics (BEAM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
The 3 Most Undervalued Gene Editing Stocks to Buy in July 2024
Artificial intelligence stocks will be the choice of growth-oriented investors for years to come. But if you're a buy-and-hold investor with above-average patience, this is a time to look for undervalued gene editing stocks.
3 Stocks With the Potential to 10X Your Money
In recent months, markets have reached new record highs, signaling that high-growth potential stocks offer opportunities to multiply earnings. The number of high-wealth individuals in the U.S. grew substantially last year alongside the stock market, partly due to notable gains among artificial intelligence (AI) stocks.
3 Stocks This Amazon-Backed AI Says Will Turn $1K into $1M by 2030
Amazon (NASDAQ: AMZN ) has more skin in the AI game than many people would like to think. Of course, the first thing that would spring to mind is the company's AWS cloud division.
